---

---

Seagen Inc.

SGEN | $228.74 0.1% 20M |

Health Technology

(0.0% 1d) (0.0% 1m) (12.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (Infinity% volume)
Earnings Calendar: 2024-02-14
Market Cap: $ 42,934,025,652
http://www.seattlegenetics.com
Sec Filling | Patents | 1605 employees


Seagen Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.

cancer   antibody   treatment  

Drugs

ADCETRIS (brentuximab vedotin)

add to watch list Paper trade email alert is off

---

Press-releases

RemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024
Published: 2024-03-11 (Crawled : 03:00) - prnewswire.com
SGEN | $228.74 0.1% 20M |

Health Technology

| Email alert Add to watchlist
rc48 presentation cancer

---

Clay Siegall
Published: 2024-03-04 (Crawled : 12:30) - shattucklabs.com
IMNM | $15.5 -9.78% -10.84% 2.1M |

Health Technology

| -32.5% | O: 0.98% H: 0.0% C: -3.74%

---

Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors
Published: 2024-03-04 (Crawled : 12:00) - globenewswire.com
GNMSF | $290.38 3.83% 220 |

Health Technology

| -3.1% | O: 0.66% H: 0.0% C: -2.86%
STTK | $9.58 -5.43% -5.74% 420K |

Health Technology

| 3.83% | O: 3.94% H: 0.0% C: -5.58%
IMNM | $15.5 -9.78% -10.84% 2.1M |

Health Technology

| -32.5% | O: 0.98% H: 0.0% C: -3.74%
GMAB | $28.72 1.38% 1.36% 360K |

Health Technology

| -2.59% | O: -2.73% H: 1.12% C: 0.07%

---

Genmab Publishes 2023 Annual Report
Published: 2024-02-14 (Crawled : 16:00) - globenewswire.com
GNMSF | $290.38 3.83% 220 |

Health Technology

| 7.15% | O: 2.65% H: 4.56% C: 1.23%
NVS | $94.36 1.93% 0.0% 2.3M |

Health Technology

| -6.04% | O: -0.02% H: 0.24% C: 0.01%
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -8.08% | O: -0.91% H: 0.0% C: 0.0%
GMAB | $28.72 1.38% 1.36% 360K |

Health Technology

| 7.95% | O: 1.32% H: 5.34% C: 3.02%
report

---

Relapsing/Refractory Multiple Myeloma Market to Observe Stupendous Growth by 2032, Estimates DelveInsight | Leading Companies - Bristol-Myers Squibb, Allogene Therapeutics, Genentech, Pfizer, Ionis Pharmaceuticals, AbbVie, Amgen
Published: 2024-01-25 (Crawled : 22:00) - prnewswire.com
ACLX | $51.67 -5.19% -5.48% 740K |

| -6.94% | O: 0.2% H: 5.99% C: 5.65%
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -8.89% | O: 0.8% H: 0.0% C: 0.0%
MTEM | $1.455 -2.02% -2.06% 13K |

Health Technology

| -60.16% | O: -2.94% H: 3.03% C: 3.03%
IONS | $40.64 -0.42% -0.42% 850K |

Health Technology

| -20.88% | O: 0.43% H: 0.27% C: -0.6%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -13.3% | O: 0.66% H: 0.64% C: -1.11%
IMAB | $1.81 0.56% 0.55% 340K |

Health Technology

| -0.55% | O: 1.1% H: 0.27% C: -1.64%
companies growth market

---

RemeGen Announces Continued Inclusion of Telitacicept and Disitamab Vedotin in China National Reimbursement Drug List, Ensuring Continuous Accessibility of Innovative Drugs for More Patients
Published: 2023-12-18 (Crawled : 13:30) - biospace.com/
SGEN | $228.74 0.1% 20M |

Health Technology

| Email alert Add to watchlist
drug china

---

Astellas and MBC BioLabs Announce 2023 Future Innovator Prize Awarded to TippingPoint Biosciences and Altay Therapeutics
Published: 2023-12-13 (Crawled : 00:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K |

Manufacturing

| -19.9% | O: -4.37% H: 5.29% C: 5.29%
SGEN | $228.74 0.1% 20M |

Health Technology

| -0.05% | O: 0.03% H: 0.01% C: -0.08%
biolabs therapeutics

---

Update: Annual Changes to the Nasdaq-100® Index
Published: 2023-12-12 (Crawled : 23:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M |

Health Technology

| -11.06% | O: -8.05% H: 1.71% C: 1.45%
TTWO 4 | $140.61 -0.02% -0.02% 2.3M |

Consumer Durables

| -8.93% | O: 2.51% H: 1.8% C: 1.23%
SGEN | $228.74 0.1% 20M |

Health Technology

| -0.05% | O: 0.03% H: 0.01% C: -0.08%
NDAQ | $60.35 0.47% 0.46% 3.1M |

Finance

| 10.78% | O: 0.11% H: 4.08% C: 3.98%
100 index

---

Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen
Published: 2023-12-12 (Crawled : 15:30) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M |

Health Technology

| -11.24% | O: -0.07% H: 0.84% C: -0.14%
SGEN | $228.74 0.1% 20M |

Health Technology

| 3.22% | O: 3.27% H: 0.0% C: 0.0%
acquisition

---

ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma
Published: 2023-12-11 (Crawled : 08:00) - biospace.com/
SGEN | $228.74 0.1% 20M |

Health Technology

| 4.73% | O: 0.73% H: 0.78% C: 0.73%
adcetris free immunotherapy trial plus

---

See all

---

Your Today's Watch List

Sign in to create a watchlist

---

Gainers vs Losers

67%

33%

Top 10 Gainers

AGBA | News | $1.26 215.0% 68.25% 130M |

Finance

EGOX | $0.0515 43.06% 30.1% 330M |

OLB 4 | $0.33 -14.95% 25.53% 840K |

Technology Services

NVFY | $2.77 31.28% 23.83% 33M |

Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M |

Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M |

Distribution Services

INSG | $3.03 25.21% 20.13% 330K |

Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K |

Manufacturing

WLGS | $0.59 18.0% 17.9% 2.3M |

ASNS | $0.828 21.75% 17.86% 18K |

---

Last 48 Hours Insiders Buying

RXO P 200000 | $19.37 2.32% 0.0% 1M |

n/a

| 23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M |

Finance

| 22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K |

Health Technology

| 22:30
BCDA P 2750 | $0.377 -1.4% 97K |

Health Technology

| 22:00
RMCF | $3.67 3.38% 3.27% 11K |

Consumer Non-Durables

| 20:10

---

12 months watchlist earnings calendar

---